32 results about "Mucosa disease" patented technology

The immunoglobulins of the present invention are useful therapeutic immunoglobulins against mucosal pathogens such as S. mutans. The immunoglobulins contain a protection protein that protects the immunoglobulins in the mucosal environment.The invention also includes the greatly improved method of producing immunoglobulins in plants by producing the protection protein in the same cell as the other components of the immunoglobulins. The components of the immunoglobulin are assembled at a much improved efficiency. The method of the invention allows the assembly and high efficiency production of such complex molecules.The invention also contemplates the production of immunoglobulins containing protection proteins in a variety of cells, including plant cells, that can be selected for useful additional properties. The use of immunoglobulins containing protection proteins as therapeutic antibodies against mucosal and other pathogens is also contemplated.

The invention relates to an antiseptic disinfectant and the preparation method of the antiseptic disinfectant, belonging to the field of medical health, which is characterized in that, vegetable oil, unsaturated carboxylic and ozone are added to a reaction column for oxidation, and then the antiseptic disinfectant is prepared; wherein the addition amount of the vegetable oil is 2kg to 4kg; the addition amount of the unsaturated carboxylic is 10ml to 25ml; the flow rate of the ozone is 120m3 / h to 1803 / h. The antiseptic disinfectant and the preparation method of the antiseptic disinfectant have the advantages that, the material adopted by the invention is the frequently used vegetable soybean oil; the preparation method is simple and the cost is low; the invention has no toxicity and side effect; ozone has broad spectrum bactericidal effect and good antibacterial activity and fungicidal activity to various aerobic microbes and anaerobic microbes of skin and mucosa diseases.

The invention provides a medicine for treating ulcer by using radix tetrastigme. The prepared medicine is characterized by containing radix tetrastigme, pharmaceutic adjuvant is added or not, and the prepared medicine can be made into oral preparation and external preparation. The medicine can be taken orally or applied externally. The medicine is effective and non-toxic when used for treating intertrigo, bedsore, diabetes mellitus, chronic ulcer caused by varicosity and ulcer or mucosa disease caused by chemoradiotherapy.

The invention discloses magnetic gel for assisting endoscopic mucosal dissection. The magnetic gel is prepared mainly from permanent magnetic material microparticles, a sodium alginate solution and acalcium chloride solution, and medical dye can also be added; a preparation method thereof comprises the following steps: preparing the sodium alginate solution, adding the permanent magnetic materialmicroparticles, uniformly mixing to obtain a solution A, and using the calcium chloride solution or a mixed solution of the calcium chloride solution and the medical dye as a solution B; filling a double-cavity synchronous injection device with the solution A and the solution B respectively, and injecting an appropriate amount of an uniformly mixed solution into a mucosal lesion to be dissected according to the size of the lesion during using, wherein the uniformly mixed solution can form the magnetic gel in the lesion within a short time. The application system comprises the double-cavity synchronous injection device for injecting the uniformly mixed solution into the mucosal lesion to be dissected, and a detachable magnetic ring at the head end of an endoscope, wherein the uniformly mixed solution forms the magnetic gel after injection. Through magnetic attraction between the magnetic gel and the detachable magnetic ring at the head end of the endoscope, a pulling force opposite toa muscular layer is provided, so that the dissection between mucosa and muscular layer is facilitated; the invention has the advantages of convenience in operation, reduction in surgical difficulty and the like.

The invention relates to a pharmaceutical composite which inhibits and / or relieves pruritus caused by dermatosis, mucosa disease or systemic disease or lesion, and is made from derivatives, salt or solvate of phenyl butyric acid and short chain fatty acid with effective dose and a carrier which is acceptable pharmaceutically.

The invention relates to an externally-applied medicine for treating skin and mucosa disease caused by human papilloma virus, which is prepared from Chinese medicinal herbs including cnidium fruit, dysosmapleiantha woods, brucea fruit, poria cocos, cordate houttuynia, flavescent sophora root and wasp's nest. The preferred dosage form of the preparation is soft electuary.

The invention provides a traditional Chinese medicinal composition for treating infantile diaper rash and a preparation method of the traditional Chinese medicinal composition. The preparation method comprises the following steps: grinding 35-45 parts of calcined gypsum into superfine powder, grinding 3-7 parts of borneol into fine powder, heating and dissolving 5-15 parts of beeswax, 35-45 parts of sesame oil and 3-7 parts of lanolin, filtering and cooling to about 65-70 DEG C; adding the borneol fine powder and dissolving the borneol fine powder, then adding the calcined gypsum superfine powder, completely stirring uniformly to be semi-solidified so as to obtain the traditional Chinese medicinal composition in ointment form. The traditional Chinese medicinal composition disclosed by the invention is used for treating infantile diaper rash caused by accumulation of damp heat, and the composition is adaptive to such fundamental symptoms as skin flushing, swelling, rash, vesicle, drainage, diabrosis and the like; and meanwhile, the traditional Chinese medicinal composition also has a relatively good treatment effect on skin mucosa diseases including inflammatory hemorrhoid, anal fissure, bedsore, herpes zoster, mosquito bite and the like.

The invention discloses a sika deer mucosal disease homologous inactivated vaccine and a preparation method thereof. The preparation method comprises the following steps: performing inoculated culture on deer source BVDV (bovine viral diarrhea / virus) to the third to sixth generations in stable cell flasks with MDBK (madin-darby bovine kidney) cells fully spread in a single layer, selecting cell flasks which are cultured for 72-144 hours and generate a cytopathic effect (CPE), repeatedly freezing and thawing after pathological change, collecting viral liquid, adding formaldehyde into the viral liquid for inactivating, mixing the inactivated viral liquid with an oil agent consisting of white oil and sorbitan, and adding aluminum stearate to obtain the sika deer mucosal disease homologous inactivated vaccine.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine compound preparation used for preventing recurrent aphthae and application thereof, wherein the traditional Chinese medicine compound preparation is prepared by using Chinese medicines as raw materials. The preparation comprises the following Chinese medicinal herbs in parts by weight: 1-3 parts of rhizome coptisdis, 8-10 parts of capejasmine, 8-10 parts of cortex moutan, 8-10 parts of radix ophiopogonis, 4-6 parts of rhizome cimicifugae, 12-15 parts of rhizome phragmitis and 8-10 parts of raw cattail pollen. The preparation used for preventing recurrent aphthae can be used for treating mouth mucosa diseases, such as oral erosive lichen planus (OLP), chronic glossitis, glossopyrosis syndrome, behcet's diseases and chronic gingivitis.

Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

The present invention provides the use of a molybdenum and / or tungsten-containing compound in resisting human papilloma virus (HPV) or herpes virus (HSV). As an antiviral substance, the compound containing molybdenum and / or tungsten can quickly kill and permanently inhibit pathogenic microorganisms (bacteria, viruses and molds) and multi-drug-resistant bacteria; the traditional Chinese medicine composition can be used for treating and relieving various symptoms caused by human papilloma virus HPV and herpes virus HSV, and has the advantages of quick effect and strong disinfection activity, and the antiviral substances are not absorbed by the human body and do not generate toxic and side effects; the compound can be used for reducing the load of local human papilloma virus (HPV) and herpes virus (HSV) of a human body, and can also be used for preparing medicines, medical instruments, disinfectants and other auxiliary nursing products for treating various human skin or skin mucosa diseases caused by pathogenic microorganisms.

The invention relates to drugs for treating mouth mucosa diseases and the manufacture field of the drugs for treating mouth mucosa diseases, in particular to a mouth mucosa drug sustained release preparation for treating a mouth periodontal disease by doxycycline. The preparation is composed of a mouth mucosa contacted layer and a non-adhesiveness sealing layer. The mouth mucosa contacted layer comprises, by weight, 2-20 / 80-98 of antibiotic drugs and auxiliary materials. The components of the non-adhesiveness sealing layer are non-adhesiveness low water-solubility high-molecular polymers. The non-adhesiveness low water-solubility high-molecular polymers are chosen from polyvinyl alcohol. The components of mouth mucosa drug sustained release preparation comprise 2.0g of methyl vinyl ether-maleic anhydride copolymers, 2.0g of polyoxyethylene, 2.0g of carboxymethyl cellulose sodium, 12.0g of natural starch, 2.0g of menthol and 0.5g of doxycycline, and the rest is poval. The mouth mucosa drug sustained release preparation has the advantages that drug delivering is convenient, drug releasing time is long, drug releasing speed is even, targeting is strong, and adhesive force with mucosas is strong. In addition, the manufacturing method is simple in operation, low in cost, environment-friendly and suitable for industrial production.

An immunomodulatory compound is utilized to treat mucosa disease.

The invention relates to drugs for treating mouth mucosa diseases and the manufacture field of the drugs for treating mouth mucosa diseases, in particular to a mouth mucosa drug sustained release preparation for treating a mouth periodontal disease by doxycycline. The preparation is composed of a mouth mucosa contacted layer and a non-adhesiveness sealing layer. The mouth mucosa contacted layer comprises, by weight, 2-20 / 80-98 of antibiotic drugs and auxiliary materials. The components of the non-adhesiveness sealing layer are non-adhesiveness low water-solubility high-molecular polymers. The non-adhesiveness low water-solubility high-molecular polymers are chosen from polyvinyl alcohol. The components of mouth mucosa drug sustained release preparation comprise 2.0g of methyl vinyl ether-maleic anhydride copolymers, 2.0g of polyoxyethylene, 2.0g of carboxymethyl cellulose sodium, 12.0g of natural starch, 2.0g of menthol and 0.5g of doxycycline, and the rest is poval. The mouth mucosa drug sustained release preparation has the advantages that drug delivering is convenient, drug releasing time is long, drug releasing speed is even, targeting is strong, and adhesive force with mucosas is strong. In addition, the manufacturing method is simple in operation, low in cost, environment-friendly and suitable for industrial production.

Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

The invention discloses a single pure plant extract for preventing and treating skin and mucosa diseases caused by humanpapillomavirus infection in the technical field of prevention and treatment of humanpapillomavirus infection. Wild hawthorn seeds are used as raw materials, and a preparation method of the single pure plant extract comprises the following steps of: (1) repeatedly washing the wildhawthorn seeds with clear water, naturally airing, and then grinding out by using a grinding machine to prepare finished wild hawthorn seeds; (2) putting the finished wild hawthorn seeds into a fumigation gasifier, and distilling at normal pressure for 18-24 hours to obtain a wild hawthorn seed distillate oil stock solution; and (3) putting the wild hawthorn seed distillate oil stock solution into a separator, standing for 12-18 days, distilling for the first time, continuously standing for 5-8 days, and distilling for the second time to obtain a product. The single pure plant extract disclosed by the invention has a good killing effect on escherichia coli, staphylococcus aureus and candida albicans, and has a good effect on removing condyloma acuminatum, skin warts, warts and cervical high-risk viruses.

The invention relates to the technical field of oral mucosa disease treatment, in particular to a traditional Chinese medicine formula for treating skin and mucosa diseases. The traditional Chinese medicine formula comprises 10-15g of radix rehmanniae, 10-15g of folium phyllostachys, 10-30g of rhizoma anemarrhenae, 10-40g of rhizoma coptidis, 5-15g of caulis akebiae, 5-20g of radix glycyrrhizae, 20-40g of radix ginseng, 10-15g of rhizoma zingiberis, 15-30g of fructus ziziphi jujubae, 6-18g of rhizoma pinelliae, 5-15g of radix scutellariae, 10-15g of cortex phellodendri, 8-16g of fructus gardeniae, 5-10g of radix et rhizoma rhei, 6-10g of herba dendrobii, 10-15g of herba selaginellae moellendorfii and 5-12g of flos jasmini. The traditional Chinese medicine formula not only can treat the oral mucosa diseases, but also has a liver protection effect, and can effectively protect liver cells from being interfered by external factors, and accordingly, the liver protection effect is achieved, and recovery and treatment effects on the oral mucosa diseases are good.

The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: E. coli) and fungi (b: Pathogen yeast and c: Penicillium).a) Escherichia coli (additionally silver (“Ag”) as control),b) Candida parapsilosis, c) Penicillium notatum.

The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: E. coli) and fungi (b: Pathogen is yeast and c: Penicillium).a) Escherichia coli (additionally silver (“Ag”) as control),b) Candida parapsilosis, c) Penicillium notatum;

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine compound preparation used for preventing recurrent aphthae and application thereof, wherein the traditional Chinese medicine compound preparation is prepared by using Chinese medicines as raw materials. The preparation comprises the following Chinese medicinal herbs in parts by weight: 1-3 parts of rhizome coptisdis, 8-10 parts of capejasmine, 8-10 parts of cortex moutan, 8-10 parts of radix ophiopogonis, 4-6 parts of rhizome cimicifugae, 12-15 parts of rhizome phragmitis and 8-10 parts of raw cattail pollen. The preparation used for preventing recurrent aphthae can be used for treating mouth mucosa diseases, such as oral erosive lichen planus (OLP), chronic glossitis, glossopyrosis syndrome, behcet's diseases and chronic gingivitis.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating oral mucosal diseases and application thereof.The traditional Chinese medicine composition contains radix bupleuri, honeysuckles, radix scutellariae, radix puerariae, herba schizonepetae, artemisia apiacea, fructus forsythiae and other traditional Chinese medicinal materials, and the traditional Chinese medicinal materials are prepared into a medicinal preparation. Animal model tests find that the traditional Chinese medicine composition hasa remarkable curative effect on oral mucosal diseases, especially recurrent oral ulceration, the preparation process of the preparation is simple, and large-scale production of an amplification process has been carried out.

The invention relates to a pharmaceutical composite which inhibits and / or relieves pruritus caused by dermatosis, mucosa disease or systemic disease or lesion, and is made from derivatives, salt or solvate of phenyl butyric acid and short chain fatty acid with effective dose and a carrier which is acceptable pharmaceutically.

The invention provides a pharmaceutical composition for treating oral periodontal and mucosal diseases, which is prepared from raw materials in the following weight proportions: 5-60 parts of turmeric, 3-30 parts of Coptidis Rhizoma, 10-60 parts of Angelica dahurica . The invention further discloses the preparation method and application of the pharmaceutical composition. The pharmaceutical composition of the invention has good therapeutic effects on oral periodontal and mucosal diseases such as periodontitis, oral striae diseases, oral lichen planus and the like. The pharmaceutical composition of the present invention has the advantages of novel formula, simple composition, low cost, significant curative effect, no toxic and side effects, and not easy to produce tolerance, etc., and provides clinical treatment for patients with periodontitis, oral striae diseases, oral lichen planus, and oral leukoplakia. a new drug option.

An immunomodulatory compound is utilized to treat mucosa disease.

The invention discloses magnetic gel for assisting endoscopic mucosal dissection. The magnetic gel is prepared mainly from permanent magnetic material microparticles, a sodium alginate solution and acalcium chloride solution, and medical dye can also be added; a preparation method thereof comprises the following steps: preparing the sodium alginate solution, adding the permanent magnetic materialmicroparticles, uniformly mixing to obtain a solution A, and using the calcium chloride solution or a mixed solution of the calcium chloride solution and the medical dye as a solution B; filling a double-cavity synchronous injection device with the solution A and the solution B respectively, and injecting an appropriate amount of an uniformly mixed solution into a mucosal lesion to be dissected according to the size of the lesion during using, wherein the uniformly mixed solution can form the magnetic gel in the lesion within a short time. The application system comprises the double-cavity synchronous injection device for injecting the uniformly mixed solution into the mucosal lesion to be dissected, and a detachable magnetic ring at the head end of an endoscope, wherein the uniformly mixed solution forms the magnetic gel after injection. Through magnetic attraction between the magnetic gel and the detachable magnetic ring at the head end of the endoscope, a pulling force opposite toa muscular layer is provided, so that the dissection between mucosa and muscular layer is facilitated; the invention has the advantages of convenience in operation, reduction in surgical difficulty and the like.